Vaccines Europe - 21 Feb 2022
08/02/2022 – Three new vaccine companies have joined the COVIDRIVE consortium and officially become COVIDRIVE partners. Moderna, Novavax and Valneva will further contribute to the assessment of the effectiveness of COVID-19 vaccines in Europe to support the region’s public health response and address the vaccine companies’ regulatory obligations.
COVIDRIVE consists of a unique, cross-pharma consortium of vaccine companies and research groups who are joining forces to collect real-world data on the effectiveness of COVID-19 vaccines. With the inclusion of these three newcomers, COVIDRIVE, which brings together public institutions, small and medium-sized enterprises and vaccine companies, has a total of 11 partners.
Dr Jacqueline Miller, Moderna’s Senior Vice President and Therapeutic Area Head, Infectious Disease Development, Dr Seth Toback, Senior Vice President, Global Medical Affair at Novavax and Dr Judith Perez Gomez, Valneva’s Vice-President of Medical Affairs all expressed their delight to join COVIDRIVE and their belief that public-private partnerships play a key role in fighting health threats and enabling innovation and that assessing vaccine effectiveness through real-world evidence is a key factor in putting an end to the pandemic. Read their full statements here.
Details on COVIDRIVE are available at the website https://covidrive.eu.
The master protocol can be accessed at the EU PAS register of ENCePP (EU-PAS 42328) and on the COVIDRIVE website.
To join the study as a COVIDRIVE partner or study site, email the COVIDRIVE Coordination team at firstname.lastname@example.org.
Recruiting sites: Centro Interuniversitario per la Ricerca sull’Influenza e le altre Infezioni Trasmissibili (CIRI-IT hospital network, Italy), Hospital Universitario Vall d’Hebron (HUVH, Spain), Hospital Universitario Germans Trias i Pujol (HUGTiP, Spain) and Fundación para Fomento de Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO hospital network, Spain).